Pharmaceuticals,
Год журнала:
2023,
Номер
16(10), С. 1384 - 1384
Опубликована: Сен. 29, 2023
This
comprehensive
review
delves
into
the
rapidly
evolving
arena
of
cancer
vaccines.
Initially,
we
examine
intricate
constitution
tumor
microenvironment
(TME),
a
dynamic
factor
that
significantly
influences
heterogeneity.
Current
research
trends
focusing
on
harnessing
TME
for
effective
vaccine
treatments
are
also
discussed.
We
then
provide
detailed
overview
current
state
concerning
immunity
and
mechanisms
vaccines,
describing
complex
immunological
processes
involved.
Furthermore,
conduct
an
exhaustive
analysis
contemporary
landscape
with
particular
focus
peptide
DNA/RNA-based
viral-vector-based
dendritic-cell-based
whole-cell-based
analyze
summarize
these
categories
highlighting
their
individual
advantages,
limitations,
factors
influencing
effectiveness.
In
our
survey
each
category,
commonly
used
aiming
to
readers
more
understanding
research.
delve
innovative
strategy
combining
vaccines
other
therapies.
By
studying
effects
immune
checkpoint
inhibitors,
radiotherapy,
chemotherapy,
targeted
therapy,
oncolytic
virotherapy,
establish
this
approach
can
enhance
overall
treatment
efficacy
offset
limitations
single-treatment
approaches,
offering
patients
options.
Following
this,
undertake
meticulous
entire
process
personalized
elucidating
from
design,
through
production,
clinical
application,
thus
helping
gain
thorough
its
complexities.
conclusion,
exploration
in
aims
highlight
promising
potential
treatment.
As
field
continues
evolve,
it
undeniably
holds
immense
promise
improving
patient
outcomes.
Abstract
mRNA
therapeutics
have
emerged
as
powerful
tools
for
cancer
immunotherapy
in
accordance
with
their
superiority
expressing
all
sequence‐known
proteins
vivo.
In
particular,
a
small
dosage
of
delivered
mRNA,
antigen‐presenting
cells
(APCs)
can
synthesize
mutant
neo‐antigens
and
multi‐antigens
present
epitopes
to
T
lymphocytes
elicit
antitumor
effects.
addition,
receptors
like
chimeric
antigen
receptor
(CAR),
T‐cell
(TCR),
CD134,
immune‐modulating
factors
including
cytokines,
interferons,
antibodies
specific
enhance
immunological
response
against
tumors.
With
the
maturation
vitro
transcription
(IVT)
technology,
large‐scale
pure
encoding
be
synthesized
quickly.
However,
clinical
translation
mRNA‐based
anticancer
strategies
is
restricted
by
delivering
into
target
organs
or
inadequate
endosomal
escape
efficiency
mRNA.
Recently,
there
been
some
advances
immunotherapy,
which
roughly
classified
modifications
structure
development
delivery
systems,
especially
lipid
nanoparticle
platforms.
this
review,
latest
overcoming
limitations
immunotherapies
recent
are
summarized.
Challenges
opportunities
applications
also
discussed.
Pharmaceutics,
Год журнала:
2023,
Номер
15(4), С. 1127 - 1127
Опубликована: Апрель 3, 2023
In
recent
years,
there
has
been
an
increase
in
deaths
due
to
infectious
diseases,
most
notably
the
context
of
viral
respiratory
pathogens.
Consequently,
focus
shifted
search
for
new
therapies,
with
attention
being
drawn
use
nanoparticles
mRNA
vaccines
targeted
delivery
improve
efficacy
these
vaccines.
Notably,
vaccine
technologies
denote
as
a
era
vaccination
their
rapid,
potentially
inexpensive,
and
scalable
development.
Although
they
do
not
pose
risk
integration
into
genome
are
produced
from
elements,
challenges,
including
exposing
naked
mRNAs
extracellular
endonucleases.
Therefore,
development
nanotechnology,
we
can
further
efficacy.
Nanoparticles,
nanometer
dimensions,
move
more
freely
body
and,
small
size,
have
unique
physical
chemical
properties.
The
best
candidates
transfer
lipid
(LNPs),
which
stable
biocompatible
contain
four
components:
cationic
lipids,
ionizable
polyethylene
glycols
(PEGs),
cholesterol,
used
facilitate
cytoplasmic
delivery.
this
article,
components
system
mRNA-LNP
against
lung
infections
such
influenza,
coronavirus,
syncytial
virus
reviewed.
Moreover,
provide
succinct
overview
current
challenges
potential
future
directions
field.
Theranostics,
Год журнала:
2024,
Номер
14(2), С. 738 - 760
Опубликована: Янв. 1, 2024
The
mRNA
vaccine,
a
groundbreaking
advancement
in
the
field
of
immunology,
has
garnered
international
recognition
by
being
awarded
prestigious
Nobel
Prize,
which
emerged
as
promising
prophylactic
and
therapeutic
modality
for
various
diseases,
especially
cancer,
rare
disease,
infectious
disease
such
COVID-19,
wherein
successful
treatment
can
be
achieved
improving
stability
introducing
safe
effective
delivery
system.
Nanotechnology-based
systems,
lipid
nanoparticles,
lipoplexes,
polyplexes,
lipid-polymer
hybrid
nanoparticles
others,
have
attracted
great
interest
been
explored
delivery.
Nanoscale
platforms
protect
from
extracellular
degradation
while
promoting
endosome
escape
after
endocytosis,
hence
efficacy.
This
review
provides
an
overview
diverse
nanoplatforms
utilized
preclinical
clinical
stages,
including
formulation,
preparation
process,
transfection
efficiency,
administration
route.
Furthermore,
market
situation
prospects
vaccines
are
discussed
here.
Journal of Nanobiotechnology,
Год журнала:
2024,
Номер
22(1)
Опубликована: Июль 4, 2024
Abstract
Messenger
RNA
(mRNA)
has
emerged
as
a
promising
therapeutic
molecule
with
numerous
clinical
applications
in
treating
central
nervous
system
disorders,
tumors,
COVID-19,
and
other
diseases.
mRNA
therapies
must
be
encapsulated
into
safe,
stable,
effective
delivery
vehicles
to
preserve
the
cargo
from
degradation
prevent
immunogenicity.
Exosomes
have
gained
growing
attention
because
of
their
good
biocompatibility,
low
immunogenicity,
small
size,
unique
capacity
traverse
physiological
barriers,
cell-specific
tropism.
Moreover,
these
exosomes
can
engineered
utilize
natural
carriers
target
specific
cells
or
tissues.
This
targeted
approach
will
enhance
efficacy
reduce
side
effects
mRNAs.
However,
difficulties
such
lack
consistent
reliable
methods
for
exosome
purification
efficient
encapsulation
large
mRNAs
addressed.
article
outlines
current
breakthroughs
cell-derived
vesicle-mediated
its
biomedical
applications.
Graphical
Journal of Controlled Release,
Год журнала:
2021,
Номер
338, С. 201 - 210
Опубликована: Авг. 18, 2021
Self-amplifying
RNA
(saRNA)
is
a
next-generation
vaccine
platform,
but
like
all
nucleic
acids,
requires
delivery
vehicle
to
promote
cellular
uptake
and
protect
the
saRNA
from
degradation.
To
date,
platforms
for
have
included
lipid
nanoparticles
(LNP),
polyplexes
cationic
nanoemulsions;
of
these
LNP
are
most
clinically
advanced
with
recent
FDA
approval
COVID-19
based-modified
mRNA
vaccines.
While
effect
on
immunogenicity
well
studied,
role
biomaterials
in
effectiveness
under
investigated.
Here,
we
tested
formulated
either
pABOL,
bioreducible
polymer,
or
LNP,
characterized
protein
expression
both
platforms.
We
observed
that
pABOL-formulated
resulted
higher
magnitude
expression,
formulations
were
overall
more
immunogenic.
Furthermore,
helper
phospholipid
route
administration
(intramuscular
versus
intranasal)
impacted
two
model
antigens
(influenza
hemagglutinin
SARS-CoV-2
spike
protein).
administered
intramuscularly,
not
pABOL
intranasally,
increased
acute
interleukin-6
after
vaccination.
Overall,
results
indicate
systems
routes
may
fulfill
different
niches
within
field
genetic
medicines.
ACS Nano,
Год журнала:
2021,
Номер
15(11), С. 17582 - 17601
Опубликована: Окт. 27, 2021
The
COVID-19
pandemic
is
caused
by
the
coronavirus
SARS-CoV-2
(SC2).
A
variety
of
anti-SC2
vaccines
have
been
approved
for
human
applications,
including
those
using
messenger
RNA
(mRNA),
adenoviruses
expressing
SC2
spike
(S)
protein,
and
inactivated
virus.
protective
periods
immunization
afforded
these
intramuscularly
administered
are
currently
unknown.
An
alternative
self-administrable
vaccine
capable
mounting
long-lasting
immunity
via
sterilizing
neutralizing
antibodies
would
be
hugely
advantageous
in
tackling
emerging
mutant
variants.
This
could
also
diminish
possibility
vaccinated
individuals
acting
as
passive
carriers
COVID-19.
Here,
we
investigate
potential
an
intranasal
(IN)-delivered
DNA
encoding
S
protein
BALB/c
C57BL/6J
immunocompetent
mouse
models.
immune
response
to
IN
delivery
this
SC2-spike
transported
on
a
modified
gold-chitosan
nanocarrier
shows
strong
consistent
surge
(IgG,
IgA,
IgM)
effective
neutralization
pseudoviruses
proteins
different
variants
(Wuhan,
beta,
D614G).
Immunophenotyping
histological
analyses
reveal
chronological
events
involved
recognition
antigen
resident
dendritic
cells
alveolar
macrophages,
which
prime
draining
lymph
nodes
spleen
peak
SC2-specific
cellular
humoral
responses.
attainable
high
levels
IgA
lung
mucosa
tissue-resident
memory
T
can
efficiently
inhibit
its
at
site
entry
provide
immunity.
Journal of Tissue Engineering,
Год журнала:
2022,
Номер
13
Опубликована: Янв. 1, 2022
In
the
past
decade,
microneedle-based
drug
delivery
systems
showed
promising
approaches
to
become
suitable
and
alternative
for
hypodermic
injections
can
control
agent
without
side
effects
compared
conventional
approaches.
Despite
these
advantages,
procedure
of
microfabrication
is
facing
some
difficulties.
For
instance,
loading
method,
stability
drugs,
retention
time
are
subjects
debate.
Besides,
application
novel
refining
fabrication
methods,
types
materials,
instruments
other
issues
that
need
further
attention.
Herein,
we
tried
summarize
recent
achievements
in
controllable
(microneedle
patches)
vitro
vivo
settings.
addition,
discussed
influence
delivered
drugs
on
cellular
mechanism
immunization
molecular
signaling
pathways
through
intradermal
route.
Understanding
putative
efficiency
microneedle
patches
human
medicine
help
us
develop
design
sophisticated
therapeutic
modalities.
ACS Nano,
Год журнала:
2022,
Номер
16(11), С. 18936 - 18950
Опубликована: Окт. 21, 2022
Ionizable
cationic
lipid-containing
lipid
nanoparticles
(LNPs)
are
the
most
clinically
advanced
non-viral
gene
delivery
platforms,
holding
great
potential
for
therapeutics.
This
is
exemplified
by
two
COVID-19
vaccines
employing
mRNA-LNP
technology
from
Pfizer/BioNTech
and
Moderna.
Herein,
we
develop
a
chemical
library
of
ionizable
lipids
through
one-step
chemical-biological
enzyme-catalyzed
esterification
method,
synthesized
were
further
prepared
to
be
LNPs
mRNA
delivery.
Through
orthogonal
design
experiment
methodology
screening,
top-performing
AA3-DLin
show
outstanding
efficacy
long-term
storage
capability.
Furthermore,
LNP
encapsulating
SARS-CoV-2
spike
mRNAs
successfully
induced
strong
immunogenicity
in
BALB/c
mouse
model
demonstrated
antibody
titers,
virus
challenge,
T
cell
immune
response
studies.
The
developed
an
excellent
platform,
this
study
provides
overall
perspective
lipids,
aspects
design,
synthesis,
optimization,
fabrication,
characterization,
application.
Theranostics,
Год журнала:
2022,
Номер
12(9), С. 4081 - 4109
Опубликована: Янв. 1, 2022
Nucleic
acid
vaccines,
especially
messenger
RNA
(mRNA)
display
unique
benefits
in
the
current
COVID-19
pandemic.The
application
of
polymeric
materials
as
delivery
carriers
has
greatly
promoted
nucleic
vaccine
a
promising
prophylactic
and
therapeutic
strategy.The
inherent
properties
render
vaccines
with
excellent
vivo
stability,
enhanced
biosafety,
specific
cellular
uptake,
endolysosomal
escape,
antigen
expression.Although
progressed
significantly
past
decades,
clinical
translation
polymer-gene
systems
still
faces
insurmountable
challenges.This
review
summarizes
diverse
polymers
their
characterizations
representative
formulations
for
delivery.We
also
discussed
existing
problems,
coping
strategies,
prospect
relevant
to
applications
carriers.This
highlights
rational
design
development
towards
meeting
goals
defending
serious
or
emerging
diseases.